JP6762363B2 - Ｐｄ−１／ｐｄｌ−１を標的とする薬物に対する応答を評価する方法 - Google Patents

Ｐｄ−１／ｐｄｌ−１を標的とする薬物に対する応答を評価する方法 Download PDF

Info

Publication number
JP6762363B2
JP6762363B2 JP2018529539A JP2018529539A JP6762363B2 JP 6762363 B2 JP6762363 B2 JP 6762363B2 JP 2018529539 A JP2018529539 A JP 2018529539A JP 2018529539 A JP2018529539 A JP 2018529539A JP 6762363 B2 JP6762363 B2 JP 6762363B2
Authority
JP
Japan
Prior art keywords
vhl
cancer
loss
gene
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500870A5 (https=
JP2019500870A (ja
Inventor
セーラム・シュアイブ
ユスラ・メサイ
ムハンマド・ザイーム・ノマン
Original Assignee
アンスティテュ・ギュスターヴ・ルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンスティテュ・ギュスターヴ・ルシー filed Critical アンスティテュ・ギュスターヴ・ルシー
Publication of JP2019500870A publication Critical patent/JP2019500870A/ja
Publication of JP2019500870A5 publication Critical patent/JP2019500870A5/ja
Application granted granted Critical
Publication of JP6762363B2 publication Critical patent/JP6762363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018529539A 2015-12-18 2016-12-16 Ｐｄ−１／ｐｄｌ−１を標的とする薬物に対する応答を評価する方法 Active JP6762363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307050 2015-12-18
EP15307050.3 2015-12-18
PCT/EP2016/081485 WO2017103147A1 (en) 2015-12-18 2016-12-16 Method for assessing the response to pd-1/pdl-1 targeting drugs

Publications (3)

Publication Number Publication Date
JP2019500870A JP2019500870A (ja) 2019-01-17
JP2019500870A5 JP2019500870A5 (https=) 2019-12-19
JP6762363B2 true JP6762363B2 (ja) 2020-09-30

Family

ID=55129471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529539A Active JP6762363B2 (ja) 2015-12-18 2016-12-16 Ｐｄ−１／ｐｄｌ−１を標的とする薬物に対する応答を評価する方法

Country Status (5)

Country Link
US (1) US11137404B2 (https=)
JP (1) JP6762363B2 (https=)
KR (1) KR102378298B1 (https=)
IL (1) IL260024B (https=)
WO (1) WO2017103147A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101980003B1 (ko) * 2017-09-14 2019-05-17 건국대학교 글로컬산학협력단 면역체크포인트의 발현을 억제하기 위한 물질을 포함하는 나노입자 전달체
KR102216725B1 (ko) * 2017-12-29 2021-02-17 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
WO2019159825A1 (ja) * 2018-02-14 2019-08-22 国立大学法人名古屋大学 抗ｐｄ－１抗体／抗ｐｄ－ｌ１抗体療法の効果を予測するバイオマーカー
GB201805876D0 (en) * 2018-04-09 2018-05-23 Francis Crick Institute Ltd Method
JP2022533012A (ja) * 2019-04-30 2022-07-21 エックスセル・バイオサイエンシズ・インコーポレイテッド 細胞表現型を調節するための系および方法
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
KR20230125672A (ko) * 2022-02-21 2023-08-29 사회복지법인 삼성생명공익재단 암 환자에 대한 면역관문억제제의 반응성 예측용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
US11137404B2 (en) 2021-10-05
KR20180115262A (ko) 2018-10-22
WO2017103147A1 (en) 2017-06-22
IL260024A (en) 2018-07-31
IL260024B (en) 2021-07-29
KR102378298B1 (ko) 2022-03-23
JP2019500870A (ja) 2019-01-17
US20180364241A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
JP6762363B2 (ja) Ｐｄ−１／ｐｄｌ−１を標的とする薬物に対する応答を評価する方法
Dyck et al. Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function
Herpers et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR× LGR5 bispecific antibody with efficacy in epithelial tumors
Schuster et al. Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
US20250382368A1 (en) Methods of treating a non-small cell lung cancer using an anti-pd-1 antibody
Oudijk et al. SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors
Bruscoli et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice
KR20190021252A (ko) c-MAF 상태에 기초한 유방암의 치료
US20240310266A1 (en) Biomarkers for cancer and methods of use thereof
JP2018516870A (ja) ３つの完全ヒトモノクローナル抗ｅｇｆｒ抗体の組み合わせを用いて上皮成長因子受容体（ｅｇｆｒ）の細胞外ドメインに変異を有する患者を治療する方法
Jung et al. Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma
Ladd et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
JP2022516850A (ja) 骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用
JP2023113613A (ja) チェックポイント阻害薬のための予測末梢血バイオマーカー
Kemps et al. Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium
EP3391054B1 (en) Method for assessing the response to pd-1/pdl-1 targeting drugs
KR20190067897A (ko) 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법
Fukuhara et al. Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells
Xiong et al. DEPTOR suppresses lymphomagenesis by promoting EGFR degradation via HUWE1 E3 ligase
WO2020005063A1 (en) Combination therapy and use thereof for treating cancer
Ruiz-Patiño et al. High Grade Meningiomas: Current Therapy Based on Tumor Biology
WO2024254596A9 (en) Compositions and methods for detection of aberrant cdk5 expression
Fort Differential effects of NRasQ61 mutations on melanoma
Terragna et al. CKS1B OVER-EXPRESSION SIGNIFICANTLY PREDICTS FOR A LOWER RATE OF RESPONSE TO PRIMARY THERAPY WITH THALIDOMIDE-DEXAMETHASONE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Poli et al. http://stke. sciencemag. org/cgi/doi/10.1126/scisignal. 2005411

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191106

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20191106

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20191119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200811

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200908

R150 Certificate of patent or registration of utility model

Ref document number: 6762363

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250